Johnson & Johnson (NYSE:JNJ) Shares Sold by Mitchell Sinkler & Starr PA

Mitchell Sinkler & Starr PA reduced its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 19.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 68,640 shares of the company's stock after selling 16,731 shares during the quarter. Johnson & Johnson accounts for 2.6% of Mitchell Sinkler & Starr PA's portfolio, making the stock its 8th largest position. Mitchell Sinkler & Starr PA's holdings in Johnson & Johnson were worth $9,927,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Norges Bank bought a new stake in Johnson & Johnson during the 4th quarter worth approximately $4,390,037,000. Raymond James Financial Inc. bought a new stake in shares of Johnson & Johnson during the fourth quarter worth $1,339,878,000. Janus Henderson Group PLC increased its stake in shares of Johnson & Johnson by 228.1% in the third quarter. Janus Henderson Group PLC now owns 3,389,361 shares of the company's stock valued at $549,223,000 after buying an additional 2,356,359 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Johnson & Johnson by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company's stock valued at $33,666,460,000 after buying an additional 1,772,706 shares during the last quarter. Finally, Franklin Resources Inc. grew its holdings in Johnson & Johnson by 11.4% during the 3rd quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company's stock worth $2,721,355,000 after acquiring an additional 1,729,281 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Remove Ads

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Timothy Schmid sold 403 shares of the business's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares of the company's stock, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Robert J. Decker sold 6,999 shares of the firm's stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the transaction, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.16% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on JNJ shares. Raymond James reduced their target price on shares of Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating on the stock in a research report on Thursday, January 23rd. Argus raised Johnson & Johnson to a "strong-buy" rating in a report on Friday, January 24th. Citigroup dropped their target price on Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating for the company in a research report on Wednesday, December 11th. Bank of America raised their price target on Johnson & Johnson from $159.00 to $171.00 and gave the company a "neutral" rating in a report on Wednesday, March 5th. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $181.00 price target on shares of Johnson & Johnson in a research note on Wednesday, February 19th. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson presently has an average rating of "Moderate Buy" and an average price target of $171.33.

Johnson & Johnson Stock Performance

Shares of JNJ stock traded up $2.18 on Monday, reaching $165.89. The stock had a trading volume of 7,156,737 shares, compared to its average volume of 7,644,531. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $399.76 billion, a price-to-earnings ratio of 24.95, a P/E/G ratio of 2.56 and a beta of 0.47. The firm's 50-day moving average is $158.68 and its two-hundred day moving average is $156.07.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $22.52 billion during the quarter, compared to analysts' expectations of $22.44 billion. During the same period last year, the firm posted $2.29 earnings per share. The business's revenue was up 5.3% on a year-over-year basis. On average, research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were paid a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 2.99%. Johnson & Johnson's dividend payout ratio (DPR) is currently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.